The FDA has approved Simponi Aria (golimumab), from Janssen Biotech, for infusion for the treatment of adults with moderately to...
Janssen Biotech announced the approval of a FDA Supplemental Biologics License Application (sBLA) for Simponi Aria (golimumab for infusion) for...
New two-year results of a Phase III study showed that Simponi Aria (golimumab), from Janssen Biotech, for infusion in combination...
Janssen announced new findings from a pivotal Phase III study showing the efficacy and safety profile of the intravenously administered...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLA) to the FDA seeking approval of Simponi Aria (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate.
Janssen Research & Development announced results from the pivotal Phase III GO-VIBRANT study that showed the significant efficacy of the...
Almost half of patients with ankylosing spondylitis receiving intravenous golimumab (Simponi Aria) had a 40% improvement after 4 months of...
In its Final Appraisal Document, NICE recommends approval of Simponi (golimumab), from Merck Inc, within its marketing authorisations, as options...
The European Commission has approved Simponi (golimumab), from Janssen Biotech/Merck Inc, for the treatment of moderately to severely active Ulcerative...